Search ↗

Comparison

Sermorelin vs Somatropin

Sermorelin is GHRH analogs; Somatropin is IGF & growth factors. They are compared here because they are frequently considered against each other, not because they act alike.

Sermorelin Somatropin
Class GHRH analogs IGF & growth factors
Evidence Regulator approved Regulator approved
Human trials ~20 ~200
Half-life ~10-20 minutes ~3-5 hours (subcutaneous)
Reported range 200-500 mcg 200 mcg - 1 mg
Frequency Once daily at bedtime Once daily, indication-dependent
Routes Subcutaneous Subcutaneous, Intramuscular
FDA approved Yes Yes
Research use only No No
Banned in sport Yes Yes
Studied for Growth hormone deficiency diagnosis and paediatric treatment, Age-related GH decline, Sleep quality, Body composition Growth hormone deficiency, Short stature syndromes, HIV wasting, Short bowel syndrome
Reported side effects Injection-site erythema, Flushing, Headache, Transient dizziness Peripheral oedema, Arthralgia, Carpal tunnel syndrome, Insulin resistance, Myalgia

Sermorelin

Sermorelin is a truncated analog of growth-hormone-releasing hormone comprising residues 1-29, the minimum sequence required for receptor activation. It binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of endogenous growth hormone. Because it acts upstream on the pituitary rather than replacing growth hormone directly, release remains subject to negative feedback from somatostatin and IGF-1, which is the usual argument for a lower risk of supraphysiologic exposure than exogenous hGH.

Somatropin

Somatropin is recombinant 191-amino-acid human growth hormone, identical in sequence to the pituitary hormone. It acts directly at growth hormone receptors in liver and peripheral tissue, driving hepatic IGF-1 production, lipolysis and nitrogen retention. Unlike the secretagogues it bypasses pituitary regulation entirely, which is both why it is more predictable and why it carries the greater risk of supraphysiologic exposure and negative feedback on endogenous production.

Sermorelin vs Somatropin: common questions

What is the difference between Sermorelin and Somatropin?

Sermorelin is GHRH analogs and Somatropin is IGF & growth factors, so they act on different pathways. Sermorelin: The first 29 amino acids of endogenous growth-hormone-releasing hormone, and the shortest fragment that retains full biological activity. Somatropin: Recombinant human growth hormone itself, the reference compound every secretagogue on this site is compared against.

Which has stronger evidence, Sermorelin or Somatropin?

They sit at the same evidence level: regulator approved. Sermorelin has about 20 human studies and Somatropin about 200.

Are Sermorelin and Somatropin FDA approved?

Both are FDA approved. Sermorelin: Diagnostic assessment of pituitary GH secretory capacity (Geref); Treatment of idiopathic growth hormone deficiency in children with growth failure (Geref, approved 1997; discontinued by the manufacturer in 2008, not for safety reasons). Somatropin: Paediatric growth hormone deficiency; Adult growth hormone deficiency; Turner syndrome; Prader-Willi syndrome; Growth failure associated with chronic kidney disease; Children born small for gestational age without catch-up growth; Idiopathic short stature; SHOX deficiency; Noonan syndrome; HIV-associated wasting or cachexia (Serostim); Short bowel syndrome (Zorbtive, no longer marketed).

References

Regulatory and primary sources

  1. PubChem compound record (CID 16132413) ↗ · structure, identifiers, synonyms
  2. DailyMed: FDA-approved labeling for Sermorelin ↗ · indications, dosing, warnings as approved
  3. FDA Drugs@FDA database ↗ · approval history
  4. WADA Prohibited List ↗ · current year
  5. CAS Registry Number 86168-78-7 ↗ · chemical identity
  6. PubChem compound record (CID 137552069) ↗ · structure, identifiers, synonyms
  7. DailyMed: FDA-approved labeling for Somatropin ↗ · indications, dosing, warnings as approved
  8. FDA Drugs@FDA database ↗ · approval history
  9. CAS Registry Number 12629-01-5 ↗ · chemical identity

Published literature

  1. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  2. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  3. Memdouh S, Gavrilović I, Ng K, et al.. Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug Test Anal 2021.PubMed 34665524 · doi:10.1002/dta.3183
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?.Clin Interv Aging 2006.PubMed 18046908 · doi:10.2147/ciia.2006.1.4.307
  5. Ramirez G, Herrera R, Pineda D, et al.. The effects of high altitude on hypothalamic-pituitary secretory dynamics in men.Clin Endocrinol (Oxf) 1995.PubMed 7641401 · doi:10.1111/j.1365-2265.1995.tb01887.x
  6. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
  7. Popovic V, Pekic S, Golubicic I, et al.. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.J Clin Endocrinol Metab 2002.PubMed 11994347 · doi:10.1210/jcem.87.5.8485
  8. Saenger P, Pescovitz OH, Bercu BB, et al.. Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone.Endocrine 2001.PubMed 11572326 · doi:10.1385/ENDO:15:1:051
  9. Bidlingmaier M, Strasburger CJ. Growth hormone.Handb Exp Pharmacol 2010.PubMed 20020365 · doi:10.1007/978-3-540-79088-4_8
  10. Deal CL, Steelman J, Vlachopapadopoulou E, et al.. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.J Clin Endocrinol Metab 2022.PubMed 35405011 · doi:10.1210/clinem/dgac220
  11. Bidlingmaier M, Wu Z, Strasburger CJ. Doping with growth hormone.J Pediatr Endocrinol Metab 2001.PubMed 11592563 · doi:10.1515/jpem-2001-0802
  12. Pfäffle R, Kiess W. GH and IGF-1 Replacement in Children.Handb Exp Pharmacol 2020.PubMed 31932988 · doi:10.1007/164_2019_337
  13. Wang K, Ye F, Wang DY, et al.. Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: a meta-analysis of randomized controlled trials.BMC Pediatr 2024.PubMed 39696162 · doi:10.1186/s12887-024-05301-0
  14. Thornton PS, Maniatis AK, Aghajanova E, et al.. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.J Clin Endocrinol Metab 2021.PubMed 34272849 · doi:10.1210/clinem/dgab529
  15. Blunden C, Nasomyont N, Backeljauw P. Growth Hormone Therapy for Turner Syndrome.Pediatr Endocrinol Rev 2018.PubMed 30378785 · doi:10.17458/per.vol16.2018.bnb.ghtherapyturnersyndrome
  16. Goldsmith DR, Wagstaff AJ. Mammalian cell-derived somatropin : a review of its use in the management of HIV-associated wasting.Drugs 2006.PubMed 16526830 · doi:10.2165/00003495-200666030-00014

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.